Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
Novo Nordisk A/S: Semaglutide 2.4 mg demonstrates superior improvement in both liver fibrosis and MASH resolution in the ESSENCE trial
Friday, November 01, 2024Novo Nordisk today announced the headline results from part of the ongoing ESSENCE trial a pivotal phase week doubleblinded trial in adults with metabolic dysfunctionassociated steatohepatitis MASH and moderate to advanced liver fibrosis
ScaleReady Announces a G-Rex® Grant has been awarded to Luminary Therapeutics
Tuesday, October 29, 2024ScaleReady in collaboration with Wilson Wolf Manufacturing and BioTechne Corporation today announced that Luminary Therapeutics has been awarded a GRex Grant Luminarys GRex Grant will enable expeditious process development and INDenabling studies of...
Fasenra approved in the EU for eosinophilic granulomatosis with polyangiitis
Monday, October 28, 2024AstraZenecas Fasenra benralizumab has been approved in the European Union EU as an addon treatment for adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis EGPA EGPA is a rare immunemediated vasculitis that can re...
Accelerate antibody capture with Sartobind® Rapid A Lab for fast, flexible, and future-proof affinity chromatography
Monday, October 28, 2024The life science group Sartorius is launching Sartobind Rapid A Lab the latest innovation in our portfolio of laboratory separation technologies Featuring the fastest Protein A matrix on the market this groundbreaking affinity chromatography
AbbVie and Gedeon Richter Announce New Collaboration for the Discovery and Development of Novel Targets for Neuropsychiatric Conditions
Friday, October 25, 2024AbbVie and Gedeon Richter Plc Richter today announced a new discovery codevelopment and license agreement to advance novel targets for the potential treatment of neuropsychiatric conditions This collaboration expands upon the success of nearly two de...
Orchard Therapeutics Announces Multiple Data Presentations and Publications
Thursday, October 24, 2024Orchard Therapeutics recently acquired by Kyowa Kirin with the goal of accelerating the delivery of new gene therapies to patients around the globe today announced multiple data presentations and publications highlighting the transformative potential...
BD and Ypsomed Collaborate to Advance Self-Injection Systems for High Viscosity Biologics
Thursday, October 24, 2024BD Becton Dickinson and Company a leading global medical technology company announced a strategic collaboration with Ypsomed a leading developer of injection systems to advance selfinjection solutions for highviscosity biologic drugs In a joint proje...
Kronos Bio Data Presentation at EORTC-NCI-AACR Symposium Highlights the Importance of p300 KAT Inhibition in HPV-Driven Tumors
Wednesday, October 23, 2024Kronos Bio Inc a company dedicated to developing small molecule therapeutics that address cancers and autoimmune diseases driven by deregulated transcription today announced preclinical data from its p KAT inhibitor program
Lonza Extends Collaboration with Major Pharmaceutical Partner for Integrated Commercial Supply of Antibody-Drug Conjugates
Tuesday, October 22, 2024Lonza a global manufacturing partner to the pharmaceutical biotech and nutraceutical markets announced today a longterm extension of its collaboration with a major global biopharmaceutical partner for commercialscale manufacture of ADCs The extended...
UCB Announces Bepranemab Phase 2a Study Results Accepted for Late-Breaking Presentation at Clinical Trials on Alzheimer’s Disease (CTAD) 2024 Meeting
Tuesday, October 22, 2024UCB today announced that the results of its doubleblind TOGETHER AH Phase a study of bepranemab an investigational antitau antibody in people living with prodromal to mild Alzheimers Disease AD have been accepted for presentation in a latebreaking...
